Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- University Hospital, Antwerp
- Enrollment
- 107
- Locations
- 11
- Primary Endpoint
- testing turn around time (in days)
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
This is an observational study to evaluate the feasibility of the implementation of a personalized treatment strategy based on specific tumor marker (f.i. EGFR-mutation) in the routine clinical care setting in the Antwerp region (Belgium).
Detailed Description
The favourable results of a number of phase III-trials with gefitinib in NSCLC patients with activating EGFR-mutations, have resulted in the licensing of gefitinib in this indication. This offers the prospect of a true personalized treatment of patients with NSCLC. Implementation of such a personalized treatment strategy is dependent both on the availability of adequate tumor samples for the EGFR-mutation analysis and on the timely reporting of the mutation analysis results. Ideally the results should be available in all patients within 2 weeks of the analysis request.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age 18 years or above
- •newly diagnosed NSCLC
- •written informed consent
- •tumor sample available
Exclusion Criteria
- •mixed histology of small cell and NSCLC
Outcomes
Primary Outcomes
testing turn around time (in days)
Time Frame: up to 1 month
how long does it take to get the mutation analysis result
Secondary Outcomes
- demographics(baseline)
- correlation between pulmonary function/pulmonary antecedents and EGFR-mutation status(baseline)
- correlation between family history with regards to cancer and EGFR-mutation status(baseline)